Yue Qiu, Yuhui Chen, Li Zhu, Hongye Chen, Yongjing Dai, Baoshi Bao, Lin Tian, Xiaopeng Hao, Jiandong Wang
{"title":"化生性乳腺癌与非特异性浸润性乳腺癌临床病理特征的差异及预后分析。","authors":"Yue Qiu, Yuhui Chen, Li Zhu, Hongye Chen, Yongjing Dai, Baoshi Bao, Lin Tian, Xiaopeng Hao, Jiandong Wang","doi":"10.1155/2022/2500594","DOIUrl":null,"url":null,"abstract":"<div>\n <p><i>Introduction</i>. Metaplastic breast carcinoma is a rare special type of breast cancer, which has distinguished clinical characteristics. We aimed to evaluate the clinicopathological features of metaplastic breast carcinoma compared with nonspecific invasive breast carcinoma and study the prognosis of metaplastic breast carcinoma. <i>Methods</i>. We reviewed metaplastic breast carcinoma cases (<i>n</i> = 37) from January 2000 to December 2021 and nonspecific invasive breast carcinoma cases (<i>n</i> = 433) from January 2019 to December 2020 extracted from our institution retrospectively. The following variables were recorded, including the patients’ general information, complications, T stage, expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67, molecular subtyping, lymph node status, skin or chest wall involvement, vessel carcinoma embolus, therapy modality (surgical treatments, chemotherapy, and radiotherapy), and survival. <i>Results</i>. Patients with metaplastic breast carcinoma had more advanced disease than patients with nonspecific invasive breast carcinoma (T stage: <i>P</i> = 0.0011). A greater proportion of metaplastic breast carcinoma presented with triple-negative breast cancer than nonspecific invasive breast carcinoma (79.41% vs. 12.47%, <i>P</i> ≤ 0.001). Our study showed that the skin or chest wall invasion was more frequent in metaplastic breast carcinoma patients (11.76% vs. 1.62%, <i>P</i> = 0.005). The 5-year survival rate for metaplastic breast carcinoma patients was 57.66% (95% CI: 0.3195∼0.7667). No local recurrence was observed while distant metastasis occurred in 33.33% of patients with metaplastic breast carcinoma. Death due to disease occurred in 24.24% of patients with metaplastic breast carcinoma. <i>Conclusion</i>. The majority of metaplastic breast carcinoma patients had more advanced disease and triple-negative disease than nonspecific invasive breast carcinoma patients. Also, metaplastic breast carcinoma patients had frequent skin or chest wall invasion and a high rate of distant metastasis and mortality.</p>\n </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2022 1","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2022-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424033/pdf/","citationCount":"0","resultStr":"{\"title\":\"Differences of Clinicopathological Features between Metaplastic Breast Carcinoma and Nonspecific Invasive Breast Carcinoma and Prognostic Profile of Metaplastic Breast Carcinoma\",\"authors\":\"Yue Qiu, Yuhui Chen, Li Zhu, Hongye Chen, Yongjing Dai, Baoshi Bao, Lin Tian, Xiaopeng Hao, Jiandong Wang\",\"doi\":\"10.1155/2022/2500594\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n <p><i>Introduction</i>. Metaplastic breast carcinoma is a rare special type of breast cancer, which has distinguished clinical characteristics. We aimed to evaluate the clinicopathological features of metaplastic breast carcinoma compared with nonspecific invasive breast carcinoma and study the prognosis of metaplastic breast carcinoma. <i>Methods</i>. We reviewed metaplastic breast carcinoma cases (<i>n</i> = 37) from January 2000 to December 2021 and nonspecific invasive breast carcinoma cases (<i>n</i> = 433) from January 2019 to December 2020 extracted from our institution retrospectively. The following variables were recorded, including the patients’ general information, complications, T stage, expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67, molecular subtyping, lymph node status, skin or chest wall involvement, vessel carcinoma embolus, therapy modality (surgical treatments, chemotherapy, and radiotherapy), and survival. <i>Results</i>. Patients with metaplastic breast carcinoma had more advanced disease than patients with nonspecific invasive breast carcinoma (T stage: <i>P</i> = 0.0011). A greater proportion of metaplastic breast carcinoma presented with triple-negative breast cancer than nonspecific invasive breast carcinoma (79.41% vs. 12.47%, <i>P</i> ≤ 0.001). Our study showed that the skin or chest wall invasion was more frequent in metaplastic breast carcinoma patients (11.76% vs. 1.62%, <i>P</i> = 0.005). The 5-year survival rate for metaplastic breast carcinoma patients was 57.66% (95% CI: 0.3195∼0.7667). No local recurrence was observed while distant metastasis occurred in 33.33% of patients with metaplastic breast carcinoma. Death due to disease occurred in 24.24% of patients with metaplastic breast carcinoma. <i>Conclusion</i>. The majority of metaplastic breast carcinoma patients had more advanced disease and triple-negative disease than nonspecific invasive breast carcinoma patients. Also, metaplastic breast carcinoma patients had frequent skin or chest wall invasion and a high rate of distant metastasis and mortality.</p>\\n </div>\",\"PeriodicalId\":56326,\"journal\":{\"name\":\"Breast Journal\",\"volume\":\"2022 1\",\"pages\":\"\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2022-08-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424033/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1155/2022/2500594\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Journal","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/2022/2500594","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
摘要:化生性乳腺癌是一种罕见的特殊类型的乳腺癌,具有独特的临床特征。我们的目的是比较化生性乳腺癌与非特异性浸润性乳腺癌的临床病理特征,并探讨化生性乳腺癌的预后。方法:回顾性分析我院2000年1月至2021年12月的37例化脓性乳腺癌病例和2019年1月至2020年12月的433例非特异性浸润性乳腺癌病例。记录患者一般情况、并发症、T分期、雌激素受体、孕激素受体、人表皮生长因子受体2、Ki-67表达、分子分型、淋巴结状态、皮肤或胸壁受损伤、血管癌栓塞、治疗方式(手术、化疗、放疗)、生存率。结果:转移性乳腺癌患者比非特异性浸润性乳腺癌患者病程更晚(T期:P=0.0011)。三阴性乳腺癌在化生性乳腺癌中的比例高于非特异性浸润性乳腺癌(79.41% vs. 12.47%, P≤0.001)。我们的研究显示,皮肤或胸壁侵犯在化脓性乳腺癌患者中更为常见(11.76% vs. 1.62%, P=0.005)。转移性乳腺癌患者的5年生存率为57.66% (95% CI: 0.3195 ~ 0.7667)。33.33%的乳腺癌发生远处转移,但未发生局部复发。24.24%的乳腺癌化生患者死于疾病。结论:与非特异性浸润性乳腺癌患者相比,绝大多数化脓性乳腺癌患者的病情进展和三阴性程度更高。此外,转移性乳腺癌患者有频繁的皮肤或胸壁侵犯和高的远处转移率和死亡率。
Differences of Clinicopathological Features between Metaplastic Breast Carcinoma and Nonspecific Invasive Breast Carcinoma and Prognostic Profile of Metaplastic Breast Carcinoma
Introduction. Metaplastic breast carcinoma is a rare special type of breast cancer, which has distinguished clinical characteristics. We aimed to evaluate the clinicopathological features of metaplastic breast carcinoma compared with nonspecific invasive breast carcinoma and study the prognosis of metaplastic breast carcinoma. Methods. We reviewed metaplastic breast carcinoma cases (n = 37) from January 2000 to December 2021 and nonspecific invasive breast carcinoma cases (n = 433) from January 2019 to December 2020 extracted from our institution retrospectively. The following variables were recorded, including the patients’ general information, complications, T stage, expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67, molecular subtyping, lymph node status, skin or chest wall involvement, vessel carcinoma embolus, therapy modality (surgical treatments, chemotherapy, and radiotherapy), and survival. Results. Patients with metaplastic breast carcinoma had more advanced disease than patients with nonspecific invasive breast carcinoma (T stage: P = 0.0011). A greater proportion of metaplastic breast carcinoma presented with triple-negative breast cancer than nonspecific invasive breast carcinoma (79.41% vs. 12.47%, P ≤ 0.001). Our study showed that the skin or chest wall invasion was more frequent in metaplastic breast carcinoma patients (11.76% vs. 1.62%, P = 0.005). The 5-year survival rate for metaplastic breast carcinoma patients was 57.66% (95% CI: 0.3195∼0.7667). No local recurrence was observed while distant metastasis occurred in 33.33% of patients with metaplastic breast carcinoma. Death due to disease occurred in 24.24% of patients with metaplastic breast carcinoma. Conclusion. The majority of metaplastic breast carcinoma patients had more advanced disease and triple-negative disease than nonspecific invasive breast carcinoma patients. Also, metaplastic breast carcinoma patients had frequent skin or chest wall invasion and a high rate of distant metastasis and mortality.
期刊介绍:
The Breast Journal is the first comprehensive, multidisciplinary source devoted exclusively to all facets of research, diagnosis, and treatment of breast disease. The Breast Journal encompasses the latest news and technologies from the many medical specialties concerned with breast disease care in order to address the disease within the context of an integrated breast health care. This editorial philosophy recognizes the special social, sexual, and psychological considerations that distinguish cancer, and breast cancer in particular, from other serious diseases. Topics specifically within the scope of The Breast Journal include:
Risk Factors
Prevention
Early Detection
Diagnosis and Therapy
Psychological Issues
Quality of Life
Biology of Breast Cancer.